Lawrence Thomas

Lawrence Thomas has an extensive work experience in the field of preclinical research and development in the pharmaceutical and medical industries. Lawrence began their career in 1983 as a Research Associate at UMass Medical School, where they worked until 1989. Following this, they joined Mass. General Hospital / Harvard Medical School as a Postdoc from 1989 to 1992. In 1993, they became a Sr. Scientist II at T Cell Sciences, Inc and worked there until 1998. From 1998 to 2008, they worked at AVANT Immunotherapeutics as the Director of Nonclinical Research and Development. In 2008, they joined Celldex Therapeutics, initially as the Director of Preclinical Research and Development, and subsequently held roles as the Sr. Director of Preclinical Research and Development, Executive Director of Preclinical R&D, and currently serves as the Vice President of Preclinical R&D and Bioanalytics. The most recent role began in July 2020 and has no specified end date.

Lawrence Thomas has an extensive education history in the field of pharmacology and toxicology. Lawrence obtained their Ph.D. in Pharmacology from UMass Chan Medical School, where they studied from 1983 to 1988. Prior to that, Lawrence completed their undergraduate studies at Brandeis University from 1977 to 1981, earning a BA degree in Biology, Chemistry, and Biochemistry.

In addition to their formal education, Lawrence Thomas has acquired additional certifications. Lawrence is a Diplomate (DABT) certified by the American Board of Toxicology, which they obtained in 2006. Lawrence is also a European Registered Toxicologist (ERT), although the specific details of when and where they obtained this certification are not provided.